1. Home
  2. VNDA vs POLE Comparison

VNDA vs POLE Comparison

Compare VNDA & POLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VNDA
  • POLE
  • Stock Information
  • Founded
  • VNDA 2002
  • POLE 2024
  • Country
  • VNDA United States
  • POLE United States
  • Employees
  • VNDA N/A
  • POLE N/A
  • Industry
  • VNDA Biotechnology: Pharmaceutical Preparations
  • POLE
  • Sector
  • VNDA Health Care
  • POLE
  • Exchange
  • VNDA Nasdaq
  • POLE NYSE
  • Market Cap
  • VNDA 282.8M
  • POLE 296.0M
  • IPO Year
  • VNDA 2006
  • POLE 2024
  • Fundamental
  • Price
  • VNDA $4.88
  • POLE $10.12
  • Analyst Decision
  • VNDA Strong Buy
  • POLE
  • Analyst Count
  • VNDA 2
  • POLE 0
  • Target Price
  • VNDA $16.50
  • POLE N/A
  • AVG Volume (30 Days)
  • VNDA 652.5K
  • POLE 3.8K
  • Earning Date
  • VNDA 05-07-2025
  • POLE 01-01-0001
  • Dividend Yield
  • VNDA N/A
  • POLE N/A
  • EPS Growth
  • VNDA N/A
  • POLE N/A
  • EPS
  • VNDA N/A
  • POLE N/A
  • Revenue
  • VNDA $198,772,000.00
  • POLE N/A
  • Revenue This Year
  • VNDA $14.36
  • POLE N/A
  • Revenue Next Year
  • VNDA $44.53
  • POLE N/A
  • P/E Ratio
  • VNDA N/A
  • POLE N/A
  • Revenue Growth
  • VNDA 3.18
  • POLE N/A
  • 52 Week Low
  • VNDA $3.71
  • POLE $9.94
  • 52 Week High
  • VNDA $6.75
  • POLE $11.16
  • Technical
  • Relative Strength Index (RSI)
  • VNDA 52.81
  • POLE N/A
  • Support Level
  • VNDA $4.84
  • POLE N/A
  • Resistance Level
  • VNDA $5.04
  • POLE N/A
  • Average True Range (ATR)
  • VNDA 0.22
  • POLE 0.00
  • MACD
  • VNDA -0.00
  • POLE 0.00
  • Stochastic Oscillator
  • VNDA 45.61
  • POLE 0.00

About VNDA Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

About POLE ANDRETTI ACQUISITION CORP. II

Andretti Acquisition Corp II is a blank check company.

Share on Social Networks: